New York University

Other

Roy Pinchot

Norman B Javitt

Stephen R Wilson

Peter John McDonnell

Jonathan C Javitt

Richard B Stoughton

A method of determining when a subject is experiencing anaerobic exercise during an exercise session, for determining effectiveness of a training period, and/or for determining a level of lactic acid produced by a subject during an exercise session may involve the administration of a bicarbonate comprising a carbon-13 isotope. Expired air may be monitored, and a ratio of carbon dioxide comprised of the carbon-13 isotope and carbon dioxide comprised of a carbon-12 isotope may be determined at one or more points in time. Charts of the ratios may be used to indicate onset of anaerobic exercise or effectiveness of a training period, and/or the determined ratio(s) may be used to indicate lactic acid production.

Noninvasive method for measuring lactic acid and detection of anaerobic exercise for evaluating fitness

This invention relates to novel physiological oxysteroids and oxysteroid hormones which are C27 modified sterols, particularly derivatives of intermediates in cholesterol synthesis, including lanosterol, zymosterol and desmosterol, including C27 diol and C27 acid derivatives, as well as related compounds and analogs thereof. The invention relates to treatment of cholesterol-related conditions by modulating the rate of cholesterol synthesis or cholesterol metabolism by administration of the oxysteroids, analogs or antagonists thereof. Methods are provided for ameliorating, treating or preventing macular degeneration by administering an agent which stimulates the expression or activity of steroid sulphotransferase (SLUT2), particularly SLUT2B1b, or which stimulates the expression or activity of CYP27A1 or sterol 27-hydroxylase. Assays for identification of analogs, antagonists or modulators of the oxysteroids or of sterol 27-hydroxylase are provided.

Class of sterol ligands and their uses in regulation of cholesterol and gene expression

A method for preventing or reducing restenosis wherein a 27-hydroxycholesterol or a 25,26 and/or 27-aminocholesterol, or a sterol 27-hydroxylase stimulant, is administered in a restenosis preventing and/or reducing amount. The invention also includes a method for treating cancer using 27-hydroxycholesterol.

Administration of a 27-hydroxycholesterol or prodrug thereof as an

Administration of a 27-hydroxycholesterol or related compound or

A topical composition comprising an amount of a carbonic anhydrase inhibitor and an amount of .beta.-cyclodextrin derivative effective in increasing the bioavailability of the carbonic anhydrase inhibitor when coadministered topically to the eye.

Topical compositions for the eye comprising a .beta.-cyclodextrin

A method for preventing or reducing restenosis wherein a 27-hydroxycholesterol or a 25,26 and/or 27-aminocholesterol, or a sterol 27-hydroxylase stimulant is administered in a restenosis preventing and/or reducing amount.

This invention relates to cholesterol synthesis and to the accumulation and regulation of cholesterol levels in body tissue. More specifically, the invention provides that the compound 26-aminocholesterol, ##STR1## and analogs and derivatives thereof, exhibit biological activity as a potent inhibitor of cholesterol synthesis and/or cholesterol accumulation in body tissue. The compounds strongly inhibit of the enzyme HMGCoA reductase and low density lipoprotein accumulation by non-hepatic cells. Surprisingly, it has been discovered that 26-aminocholesterol is selective for fibroblast (plasma) cells, and has little or no effect on hepato (liver) cells. Therapeutic compounds according to the invention include substituted or unsubstituted sterols of the formula: ##STR2## wherein the carbon atoms at positions 5 and 6 of the sterol are one of saturated and unsaturated, R.sub.1 is one of a 3-hydroxyl group and a 3-keto group, R.sub.2 is one of a hydroxyl group and a keto group, and wherein at least one of R.sub.3, R.sub.4 and R.sub.5 is an amino group and the others are each selected from the group consisting of hydrogen and an amino group.

26-aminocholesterol and derivatives and analogs thereof in the

The invention is directed to a pharmaceutical composition comprising an oxygenated cholesterol and a penetration-enhancing agent which is useful for topical application to the skin of a patient suffering from a proliferative skin disease characterized by geminative cells having a rapid rate of replication, e.g. psoriasis. The composition comprises an effective amount for the inhibition of germinative cell mitosis of an oxygenated cholesterol, e.g. 26-hydroxycholesterol, or a pharmaceutically effective derivative thereof e.g. an ester or ether. The invention is further directed to a method of treating a patient suffering from said skin disease comprising applying to the effected skin said therapeutic composition. The invention is also directed to the topical application of these compositions to the skin to decrease inflammation.

Composition comprising an oxygenated cholesterol and use thereof for

Use of 26-hydroxycholesterol for reducing cholesterol synthesis and/or accumulation in body tissues.

Growing community of inventors

New York, NY, United States of America

Norman B Javitt